Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study

Journal des Maladies Vasculaires

Volumn 39, Issue 3, 2014, Pages 161-168

  Sevestre, M A ^a   Belizna, C ^b   Durant, C ^c   Bosson, J L ^d   Vedrine, L ^e   Cajfinger, F ^f   Debourdeau, P ^g   Farge, D ^h  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e University of Paris Descartes   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CENTRE HOSPITALIER D AVIGNON   (France)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

Neoplasms; Practice guideline; Venous thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICATION COMPLIANCE; METASTASIS; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; TREATMENT DURATION; URINARY TRACT CANCER; VENOUS THROMBOEMBOLISM; AGED; ANTIBODY SPECIFICITY; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG UTILIZATION; FOLLOW UP; FRANCE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PULMONARY EMBOLISM; RISK FACTOR; STATISTICS AND NUMERICAL DATA; THROMBOPHILIA; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASMS; ORGAN SPECIFICITY; PRACTICE GUIDELINES AS TOPIC; PULMONARY EMBOLISM; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; THROMBOPHILIA; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84901262392     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmv.2014.03.001     Document Type: Article

References (20)

1. Chew H.K., Wun T., Harvey, Zhou H., White R.H. Incidence of venous thromboembolism and its effects on survival among patients with common cancers. Arch Intern Med 2006, 166:458-464.
2. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999, 78:285-291.
3. Noble S., Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010, 13(102 Suppl. 1):S2-S9.
4. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850.
5. Sandhu R., Pan C.X., Wun T., Harvey D., Zhou H., White R.H., et al. The Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Primary Bladder Cancer. Cancer 2010, 116:2596-2603.
6. Meyer G., Marjanovic Z., Valcke J. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162:1729-1735.
7. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
8. Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006, 119:1062-1072.
9. Akl E.A., Vasireddi S.R., Gunukula S., Barba M., Sperati F., Terrenato I., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011, 15(6). [CD006649].
10. Mandala M., Falanga A., Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008, 19(Suppl. 2):126-127.
11. Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490-5505.
12. Wagman L.D., Baird M.F., Bennett C.L., Bockenstedt P.L., Cataland S.R., Fanikos J., et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:838-869.
13. Debourdeau P., Kassab-Chahmi D., Le Gal G., Kriegel I., Desruennes E., Douard M.C., et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheter in patients with cancer: report from the working group. Ann Oncol 2009, 20:1459-1471.
14. Farge D., Bosquet L., Kassab-Chahmi D., Mismetti P., Elalamy I., Meyer G., et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010, 73:31-46.
15. Lyman G.H., Khorana A.A., Kuderer N.M., Lee A.Y., Arcelus J.I., Balaban E.P., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer. ASCO practice guidelines update. J Clin Oncol 2013, 31:2189-2204.
16. Khorana A.A., Dalal M., Lin J., Conolly G.C. Incidence and predictors of venous thromboembolism among ambulatory high-risk patients undergoing chemotherapy in the United States. Cancer 2013, 119:648-655.
17. Delate T., Witt D.M., Ritzwoller D., Weeks J.C., Kushi L., Hornbrook L.C., et al. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 2012, 17:419-427.
18. Spirk D., Ugi J., Korte W., Husmann M., Hayoz D., Baldi T., et al. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. Thromb Haemost 2011, 105:962-967.
19. Farge D., Debourdeau P., Beckers M., Baglin C., Bauersachs R.M., Brenner B., et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013, 11:56-70.
20. Debourdeau P., Farge D., Beckers M., Baglin C., Bauersachs R.M., Brenner B., et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013, 11:71-80.